trending Market Intelligence /marketintelligence/en/news-insights/trending/72hlNzSz9E0vvce8Hp-C6g2 content esgSubNav
In This List

Novartis unit gains commercialization rights for Polpharma's MS biosimilar

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novartis unit gains commercialization rights for Polpharma's MS biosimilar

Novartis AG's Sandoz International GmbH unit obtained rights to commercialize a proposed biosimilar of multiple sclerosis drug natalizumab being developed by Polpharma Biologics.

Natalizumab, which is sold by Biogen Inc. as Tysabri, is being developed in a phase 3 clinical trial to treat patients with relapsing-remitting multiple sclerosis.

Financial terms of the deal were not revealed.

Relapsing-remitting multiple sclerosis is characterized by patients experiencing worsening of symptoms in between periods when symptoms decline or disappear.

Under the deal, Holzkirchen, Germany-based Sandoz will commercialize and distribute the therapy in all markets upon approval via an exclusive global license. Polpharma, a Gdańsk, Poland-based drugmaker, will be responsible for the development, manufacture and supply of natalizumab.

Sandoz has a global portfolio of eight marketed biosimilars, with over 10 more in development.

SNL Image